

FOR IMMEDIATE RELEASE

February 11 2026

ACTRIS Signs MoU with Cell Therapies Pty Ltd to Advance CDMO Capabilities for Cell and Gene Therapies

Singapore/Melbourne - Advanced Cell Therapy and Research Institute, Singapore (ACTRIS) announced today that it has signed a Memorandum of Understanding (MoU) with **Cell Therapies Pty Ltd**, Australia's leading contract development and manufacturing organisation (CDMO) for cell and gene therapies (CGT), to strengthen ACTRIS's position as a premier CGT manufacturing hub in Asia. This MoU marks the first step in a strategic collaboration aimed at accelerating ACTRIS's operational readiness and expanding patient access to advanced therapies across Singapore and the wider Asia Pacific region.

This partnership will combine ACTRIS's state-of-the-art Good Manufacturing Practice (GMP) infrastructure and vision to be a regional centre of excellence with Cell Therapies' decades of experience in CGT development, clinical translation, and commercial manufacturing. Together, the organisations will work to streamline manufacturing processes, enhance compliance, and build sustainable capabilities for CGT development and commercialisation.

Importantly, this collaboration also reflects Cell Therapies' continued commitment to strengthening its Asia Pacific Alliance Model (APAM)-a distributed network designed to enable efficient technology transfer, regional manufacturing access, and a single, coordinated pathway for global sponsors seeking to advance CGT programs across APAC.

Key Objectives of the Collaboration

- Optimize GMP-compliant manufacturing processes for CGT
- Enable efficient technology transfer and scale-up capabilities
- Strengthen regulatory strategy and compliance to meet international standards
- Build long-term infrastructure and workforce capability through training and development initiatives

This collaboration reflects a shared commitment to advancing CGT manufacturing excellence in Asia-Pacific and supporting the next generation of innovative therapies.

Statements

ACTRIS: A/Prof Aloysius Ho, Executive Director

“Signing this MoU with Cell Therapies represents a pivotal step in ACTRIS’s journey to be the national and regional centre of excellence for process development and manufacturing of cellular-based therapeutics,” said Aloysius Ho, Executive Director at ACTRIS. “Our collaboration will accelerate readiness for clinical and commercial supply, ensuring patients across the region gain timely access to life-changing therapies.”

Cell Therapies Pty Ltd: Bev Menner, CEO

“We are delighted to partner with ACTRIS to strengthen advanced manufacturing capabilities in Singapore,” said Bev Menner, CEO of Cell Therapies. “This collaboration underscores our shared commitment to building a connected CGT ecosystem across Asia Pacific, enabling streamlined pathways for clinical trials and commercial supply.”

About ACTRIS

ACTRIS was established in April 2020 to meet the increasing clinical demand for cellular therapeutics to treat various life-threatening diseases.

Its vision is to be the national and regional centre of excellence for facilitating discovery, process development, and manufacturing of cellular-based therapeutics across the broad spectrum of immunotherapy and regenerative medicine, encompassing both investigational and clinical-use products for Singapore.

Through its specialised infrastructure and skilled workforce, ACTRIS aims to promote and support the entire value chain of the cell therapy ecosystem by enabling translational research and development, manufacturing, clinical service provision, and commercialisation by serving the healthcare, academic and industrial sectors.

In addition, ACTRIS will also provide value-added services such as workforce training, regulatory support, and the standardisation of ancillary materials and product testing pertaining to the delivery of cellular therapy to patients. ACTRIS is a programme of the Consortium for Clinical Research and Innovation, Singapore (CRIS), and is supported by the Singapore Ministry of Health for its set-up and through the National Medical Research Council (NMRC) Office, MOH Holdings Pte Ltd under the NMRC RIE2025 ACTRIS Funding Initiative (MOH-001528).

For more information, please visit <https://www.actris.sg>

About Cell Therapies Pty Ltd

Cell Therapies Pty Ltd (“Cell Therapies”) is Australia’s leading CDMO dedicated to cell and gene therapies. With over two decades of experience, Cell Therapies supports the development, clinical translation, and commercial manufacture of innovative CGTs including CAR T-cell, mesenchymal stromal cells, and iPSC-derived therapies. Its facility, co-located within the Peter MacCallum Cancer Centre in Melbourne, holds licenses for clinical and commercial supply of CGTs from the Australian regulator, Therapeutic Goods Administration (TGA), and approval to supply to Japan’s market from the Japanese Ministry of Health Labor and Welfare (MHLW). Cell Therapies operates 13 purpose-built GMP cleanrooms; 10 supporting clinical trial manufacture and 3 large-scale high-throughput suites designed for commercial manufacture with a capacity of up to 2,000 patient doses annually.

Media Contact

Cell Therapies Pty Ltd:

Name: Dr Shrinidh Joshi, Director of Business Development

Email: ShrinidhJoshi@celltherapies.com

Phone: [+61 3 9492 4777](tel:+61394924777)